Compare DexCom, Inc. (DXCM) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Uranium Energy Corp — how do they compare? DexCom, Inc. trades at $77.54 (market cap $28.06B), while Uranium Energy Corp trades at $9.58 (market cap $5.00B). The key difference: DexCom, Inc. is far larger — about 5.6× Uranium Energy Corp's market cap, and DexCom, Inc. is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals.
| DXCM | UEC | |
|---|---|---|
Market Cap | $28.06B | $5.00B |
Sector | Health | Energy |
52-Week High | $89.53 | $20.14 |
52-Week Low | $54.84 | $7.63 |
Enterprise Value | $27.03B | $4.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Uranium Energy (UEC) trades at $9.62, down 7.41% today, reflecting ongoing operational challenges. The stock shows bearish technical signals with negative earnings momentum, posting a net loss of $87.66 million in 2025. Despite strong analyst support (87.5% buy ratings), fundamental metrics remain weak with a negative net income margin of -513.24% and P/S ratio of 236.29. Recent news highlights the company's strategic positioning in U.S. uranium production but emphasizes execution risks and timing uncertainties.
UEC presents a high-risk opportunity with significant execution dependency. The bullish case rests on $794 million liquidity, debt-free balance sheet, and strategic uranium assets, but investors face substantial operational risks, widening losses, and premium valuation. Near-term performance hinges on production ramp-up success and uranium price recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
